The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults

Abnormalities of the medial temporal lobe have been consistently demonstrated in schizophrenia. A common functional polymorphism, Val108/158Met, in the putative schizophrenia susceptibility gene, catechol-O-methyltransferase (COMT), has been shown to influence medial temporal lobe function. However, the effects of this polymorphism on volumes of medial temporal lobe structures, particularly in patients with schizophrenia, are less clear. Here we measured the effects of COMT Val108/158Met genotype on the volume of two regions within the medial temporal lobe, the amygdala and hippocampus, in patients with schizophrenia and healthy control subjects. We obtained MRI and genotype data for 98 schizophrenic patients and 114 matched controls. An automated atlas-based segmentation algorithm was used to generate volumetric measures of the amygdala and hippocampus. Regression analyses included COMT met allele load as an additive effect, and also controlled for age, intracranial volume, gender and acquisition site. Across patients and controls, each copy of the COMT met allele was associated on average with a 2.6% increase in right amygdala volume, a 3.8% increase in left amygdala volume and a 2.2% increase in right hippocampus volume. There were no effects of COMT genotype on volumes of the whole brain and prefrontal regions. Thus, the COMT Val108/158Met polymorphism was shown to influence medial temporal lobe volumes in a linear-additive manner, mirroring its effect on dopamine catabolism. Taken together with previous work, our data support a model in which lower COMT activity, and a resulting elevation in extracellular dopamine levels, stimulates growth of medial temporal lobe structures.

[1]  Godehard Weniger,et al.  Impaired emotional learning and reduced amygdala size in schizophrenia: a 3-month follow-up , 2004, Schizophrenia Research.

[2]  Michele T. Diaz,et al.  Voxel-based morphometric multisite collaborative study on schizophrenia. , 2009, Schizophrenia bulletin.

[3]  Abraham Z. Snyder,et al.  A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume , 2004, NeuroImage.

[4]  S. Faraone,et al.  Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. , 2003, The American journal of psychiatry.

[5]  S. Floresco,et al.  Dopaminergic Regulation of Inhibitory and Excitatory Transmission in the Basolateral Amygdala–Prefrontal Cortical Pathway , 2007, The Journal of Neuroscience.

[6]  M F Huque,et al.  Some comments on frequently used multiple endpoint adjustment methods in clinical trials. , 1997, Statistics in medicine.

[7]  P. Buckley,et al.  Catechol O-methyltransferase Val158Met Genotype and Neural Mechanisms Related to Affective Arousal and Regulation , 2008 .

[8]  S. Laviolette.  Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? , 2007, Schizophrenia bulletin.

[9]  A. Meyer-Lindenberg,et al.  Heritability of Brain Morphology Related to Schizophrenia: A Large-Scale Automated Magnetic Resonance Imaging Segmentation Study , 2008, Biological Psychiatry.

[10]  D. Velligan,et al.  Executive function in schizophrenia. , 1999, Seminars in clinical neuropsychiatry.

[11]  Thilo Deckersbach,et al.  Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[12]  並木 千尋,et al.  Impaired facial emotion recognition and reduced amygdalar volume in schizophrenia , 2008 .

[13]  P. Goldman-Rakic,et al.  Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. , 1995, Cerebral cortex.

[14]  Richard M. Weinshilboum,et al.  Pharmacogenomics: Catechol O-Methyltransferase to Thiopurine S-Methyltransferase , 2006, Cellular and Molecular Neurobiology.

[15]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[16]  M. First,et al.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV) , 2002 .

[17]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[18]  S. Burton,et al.  Symptom domains of schizophrenia: the role of atypical antipsychotic agents , 2006, Journal of psychopharmacology.

[19]  Andreas Heinz,et al.  Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex , 2005, The Journal of Neuroscience.

[20]  Daniel R. Weinberger,et al.  Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia , 2007, Human Genetics.

[21]  Jill Fries,et al.  MTHFR 677C → T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val → Met , 2008, Proceedings of the National Academy of Sciences.

[22]  James R. MacFall,et al.  The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults , 2007, Psychiatry Research: Neuroimaging.

[23]  M. Annett.  A classification of hand preference by association analysis. , 1970, British journal of psychology.

[24]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[25]  David G C Owens,et al.  Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. , 2007, Schizophrenia bulletin.

[26]  Eve C. Johnstone,et al.  Grey matter changes over time in high risk subjects developing schizophrenia , 2005, NeuroImage.

[27]  A. Caspi,et al.  Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction , 2005, Biological Psychiatry.

[28]  M. Munafo,et al.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case–control studies , 2005, Molecular Psychiatry.

[29]  F. Baas,et al.  The COMT val 158 met polymorphism and brain morphometry in healthy young adults , 2006, Neuroscience Letters.

[30]  H. Moore,et al.  Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[31]  Pat Levitt,et al.  Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D1 receptor mutant mice , 2005, The Journal of comparative neurology.

[32]  Nikos Makris,et al.  Left hippocampal volume as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric study of nonpsychotic first-degree relatives. , 2002, Archives of general psychiatry.

[33]  Gary J. Robertson,et al.  Wide‐Range Achievement Test , 2010 .

[34]  Cheryl A. Murphy,et al.  Activation of dopaminergic neurotransmission in the medial prefrontal cortex by N-methyl-d-aspartate stimulation of the ventral hippocampus in rats , 2005, Neuroscience.

[35]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[36]  T. Crow,et al.  Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. , 2005, The American journal of psychiatry.

[37]  Eve C. Johnstone,et al.  Relationship of Catechol-O-Methyltransferase Variants to Brain Structure and Function in a Population at High Risk of Psychosis , 2007, Biological Psychiatry.

[38]  K. Kendler,et al.  Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families , 2004, Molecular Psychiatry.

[39]  N. Andreasen.  Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) 1982 , 2007 .

[40]  C. Beyer,et al.  Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured embryonic mouse striatal cells , 2001, Neuroreport.

[41]  James C. Dickinson.  University of Iowa , 1888, The Dental register.

[42]  R. Murray,et al.  Meta-analysis of regional brain volumes in schizophrenia. , 2000, The American journal of psychiatry.

[43]  Wanda Fremont,et al.  Temporal lobe anatomy and psychiatric symptoms in velocardiofacial syndrome (22q11.2 deletion syndrome). , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  J. Duan,et al.  Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia , 2005, Molecular Psychiatry.

[45]  Hidehiro Iida,et al.  The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. , 2006, Brain : a journal of neurology.

[46]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[47]  S. Heckers,et al.  Neuroimaging studies of the hippocampus in schizophrenia , 2001, Hippocampus.

[48]  A. Meyer-Lindenberg,et al.  Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. , 2008, The Journal of clinical investigation.

[49]  Elena Antonova,et al.  The relationship between brain structure and neurocognition in schizophrenia: a selective review , 2004, Schizophrenia Research.

[50]  Michael D. Nelson,et al.  Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging : A meta-analytic study , 1998 .

[51]  Joseph H. Callicott,et al.  Impact of interacting functional variants in COMT on regional gray matter volume in human brain , 2009, NeuroImage.

[52]  N. Hayward,et al.  Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia , 2005, Molecular Psychiatry.

[53]  B. Kolachana,et al.  COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET , 2008, Molecular Psychiatry.

[54]  N C Andreasen,et al.  Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow , 2005, Molecular Psychiatry.

[55]  E. Phelps,et al.  The human amygdala. , 2009 .

[56]  Anders M. Dale,et al.  MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.

[57]  Clifford R. Jack,et al.  Interpreting scan data acquired from multiple scanners: A study with Alzheimer's disease , 2008, NeuroImage.

[58]  August B. Hollingshead,et al.  Two Factor Index of Social Position , 1957 .

[59]  S. Woods,et al.  Chlorpromazine equivalent doses for the newer atypical antipsychotics. , 2003, The Journal of clinical psychiatry.

[60]  Joseph H. Callicott,et al.  Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance , 2006, Psychiatry Research: Neuroimaging.

[61]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[62]  N C Andreasen,et al.  The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. , 1992, Archives of general psychiatry.